News 24.09.2019 Schlieren (Zurich), Switzerland, September 24, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces the full commercial launch of MagnetOs™ and the company’s first attendance as an exhibitor at NASS, the world’s largest spine meeting and exhibition. During the meeting, the commercial team will be...
News 09.09.2019 DUBLIN, IRELAND – SEPT 9, 2019 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and...
News 09.09.2019 Schlieren (Zurich), 9 September 2019 - LimmaTech Biologics AG today announced the start of a Phase I/II clinical trial in Kenya of a 4-valent candidate vaccine to help prevent diarrheal disease caused by the Shigella bacteria in children and infants in low and middle-income regions. This study is conducted in...
News 03.09.2019 Schlieren (Zurich), Switzerland, September 3, 2019 – Kuros Biosciences, a leader in next generation bone graft technologies, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial to evaluate the use of Fibrin-PTH (KUR-113) in...
News 27.08.2019 Research & Development: MP0250 (VEGF x HGF) in MM: PI Trial (in combination with Velcade®) – Encouraging responses observed in first patient cohorts triggered decision for further investment; IMiD Trial (in combination with Pomalyst®) – Start of phase 2 trial expected in Q4 19, having received FDA approval; MP0250 in...